BioAge Labs, Inc.
NASDAQ:BIOABiotechnology
+$0.47 today
- Market cap
- $179.59M
- Beta
- 0.95
- P/E (TTM)
- -9.7
- EPS (TTM)
- -$2.12
Volume 0.64M
Average 0.46M
BIOA Other Working Capital
Cash effect of changes in other operating assets and liabilities.
BioAge Labs, Inc.NASDAQ: BIOA
Other Working Capital · Q1 FY2026 · quarter ended Mar 2026
Other working capital declines year over year
Q1 FY2026 other working capital of $6.38M (cash outflow) fell 30.8% year over year, ahead of the -228.5% change in trailing-twelve-month other working capital. Sequentially, it rose 443.0% from the prior quarter. Over 3 fiscal years it compounded at +290.5% a year.
Context
- Other working capital amounted to 131.7% of revenue in FY2025.
- Other working capital increased in 2 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of -30.8% holds above the trailing-twelve-month pace of -228.5%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Other Working Capital history
USD · from the cash flow
- Latest · FY2025
- (11.85M) USD
- Year-over-year change
- -206.1%
| Period | Period end | Other Working Capital | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (11.85M) | -206.1% |
| FY2024 | 2024-12-31 | 11.17M | +57.3% |
| FY2023 | 2023-12-31 | 7.1M | +3669.3% |
| FY2022 | 2022-12-31 | (199K) | — |
Other Working Capital vs competitors
How BIOA compares with its peers on the latest reported figures
- Peers report in different currencies, so other working capital is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -228.5% is the 5th highest of 9, against a peer median of -165.8%.
- Other working capital amounts to 87.3% of revenue for BIOA, versus a peer median of 9.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $47.48M USD | -373.0% | — | 122.7% | |
| LTM Mar 2026 | CA$24.69M CAD | -583.4% | -6.3% | 7.9% | |
| LTM Mar 2026 | $16.02M USD | +649.3% | +102.5% | — | |
| LTM Mar 2026 | $14.42M USD | — | +27.0% | 10.7% | |
| LTM Mar 2026 | $11.83M USD | +225.4% | — | — | |
BIOABioAge Labs, Inc. | LTM Mar 2026 | $9.01M USD | -228.5% | +290.5% | 87.3% |
| LTM Mar 2026 | $6.39M USD | -465.9% | -23.3% | — | |
| LTM Mar 2026 | CA$5.67M CAD | -42.0% | -17.8% | 1.8% | |
| LTM Mar 2026 | $3.38M USD | -289.7% | — | 167.9% | |
| LTM Mar 2026 | $36K USD | +101.2% | -17.9% | 0.1% | |
| Peer median (excluding BIOA) | — | -165.8% | -12.1% | 9.3% | |
Competitors are the stored peer set for BIOA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
BioAge Labs, Inc.
NASDAQ:BIOA
Intrinsic Alpha fair value
Locked
Current Price
$4.77
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.